Monthly Archives: February 2015

Biopharmaceutical News Week 8

  February, 19, 2015 Sanofi Appoints Olivier Brandicourt as Chief Executive Officer           Olivier Brandicourt joins Sanofi from Bayer HealthCare where he was Chairman of the Board of Management and a member of the   Executive Council. Previously, Brandicourt held numerous positions of increasing responsibility within Parke-Davis/Warner-Lambert and Pfizer. A physician […]

read more

2015 A turning point for the biopharma industry?

  For quite some time now, analysts of the biopharmaceutical industry have bemoaned the industry’s lack of innovation particularly considering the vast amount of cash spent each year in research and development. Some have gone so far as to call this a ‘new molecular entity slump'. A signifiant Increase in regulatory approvals for New drugs […]

read more

Biopharmaceutical News Week7 2015

  Acquisitions /mergers/joint-ventures February 10, 2015 Roche buys German translational medicine company Signature Roche announced that it acquires German translational oncology and genomics firm Signature Diagnostics (Potsdam, Germany) for an undisclosed amount. Roche has been on the forefront of Personalized Medicine which requires access to high quality biomarkers and biobanks. Signature develops large blood plasma […]

read more

Biopharmaceutical News week 6 2015

Acquisitions /mergers/joint-ventures February 2, 2015 Icon buys MediMedia Pharma Solutions for $120 million Icon (Ireland) is to acquire MediMedia Pharma Solutions (Yardley, USA) for $120 million, creating “the industry’s leading integrated scientific communications and market access solution". Icon chief executive Ciaran Murray said “the need to demonstrate and communicate the value of new medicines is […]

read more

Biopharmaceutical News week 5 2015

Acquisitions /mergers/joint-ventures January 28, 2015 The European Commission agrees on Novartis-GSK deal The European regulators have given approval to the deal between GlaxoSmithKline and Novartis, under which the firms will exchange assets in the vaccine and the oncology field and form a new consumer healthcare joint venture, on the condition that Novartis divests two of […]

read more